A Phase 3 interventional study of HOE901-U300 (new formulation of insulin glargine) and Lantus (insulin glargine) in Type 2 Diabetes Mellitus, sponsored by Sanofi. Completed at 193 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-25.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 19th largest by enrollment of the 175 interventional ones that give a count, is one of 11 that started in 2011, is one of 60 in phase 3, and was the 96th registered.
10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Sanofi · Sites in China
Ages 18+
Loyola University · Sites in United States
Ages 18+ · Women only
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 30–65
Yanbing Li
Ages 18–70
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
176 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 11 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 807 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 253 across the 175 interventional studies. Of the 161 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
122 of 176 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
186 studies in Diabetes Mellitus, Type 2 by Sanofi: 1 open now, 1 under way, none of them phase 3. Of 183 finished, 46 (25%) have results posted.
Among the 186 studies in Diabetes Mellitus, Type 2 by Sanofi, this one is the 24th largest by enrollment of the 178 interventional ones that give a count, is one of 6 that started in 2011, is one of 80 in phase 3, and was the 105th registered.
Sanofi’s Diabetes Mellitus, Type 2 studies by the year they started, since 2000.
1 of the studies testing Insulin Glargine in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 186 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
Secondary Objectives:
The maximum study duration was up to approximately 58 weeks per participant, consisting of:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Substudy inclusion criteria:
Exclusion criteria:
Substudy exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HOE901-U300 (new formulation of insulin glargine)
Drug: Lantus (insulin glargine)
HOE901-U300 (new insulin glargine 300 units per milliliter \[U/mL\]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter \[mg/dL\]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
Also known as: Lantus
Change in HbA1c From Baseline to Month 6 Endpoint
Time frame: Baseline, Month 6
Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6 Endpoint
Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time), regardless the participant was awake or woke up because of the event. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose less than or equal to (\<=) 3.9 millimoles per liter (mmol/L) (70 milligram per deciliter \[mg/dL\]).
Time frame: Week 9 Up to Month 6
Change in Average Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Average was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit.
Time frame: Baseline, Month 6
Change in Variability of Preinjection SMPG From Baseline to Month 6 Endpoint
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit.
Time frame: Baseline, Month 6
Percentage of Participants With HbA1c <7% at Month 6 Endpoint
Time frame: Month 6
Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint
Time frame: Baseline, Month 6
Percentage of Participants With FPG <5.6 mmol/L (<100 mg/dL) at Month 6 Endpoint
Time frame: Month 6
Change in 8-Point SMPG Profiles Per Time Point From Baseline to Month 6 Endpoint
Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime.
Time frame: Baseline, Month 6
Change in Daily Basal Insulin Dose From Baseline to Month 6 Endpoint
Time frame: Baseline, Month 6
Change in Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint
DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction.
Time frame: Baseline, Month 6
Percentage of Participants With Hypoglycemia (All and Nocturnal) Events From Baseline up to Month 12
Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).
Time frame: Up to Month 12
Change in HbA1c From Month 6 to Month 9
Substudy comparing fixed dosing regimen (every 24 hours) vs. adaptive dosing regimen (every 24 +/- 3 hours) in a subset of participants randomized to HOE901-U300 and treated for 6 months.
Time frame: Month 6 Up to Month 9
A total of 1177 participants were screened, of whom 370 participants were screen failure and 807 participants were randomized.
| Milestone | HOE901-U300 | Lantus |
|---|---|---|
| Started | 404 | 403 |
| Treated | 404 | 402 |
| Participated in substudy | 109 | 0 |
| Modified intent-to-treat population | 404 | 400 |
| Completed | 359 | 355 |
| Not completed | 45 | 48 |
| Withdrew: Randomized but not treated | 0 | 1 |
| Withdrew: Adverse event | 12 | 16 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Protocol violation | 6 | 8 |
| Withdrew: Diverse reasons | 18 | 14 |
| Withdrew: Site closure for noncompliance | 5 | 2 |
| Withdrew: Hypoglycemia | 2 | 3 |
| Withdrew: Lost to follow-up | 1 | 3 |
| percentage of hemoglobin | HOE901-U300 | Lantus |
|---|---|---|
| Change in HbA1c From Baseline to Month 6 Endpoint | -0.83 ± 0.060 | -0.83 ± 0.061 |
Nocturnal hypoglycemia was hypoglycemia that occurred between 00:00 and 05:59 hours (clock time), regardless the participant was awake or woke up because of the event. Severe hypoglycemia was an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Confirmed hypoglycemia was an event associated with plasma glucose less than or equal to (\<=) 3.9 millimoles per liter (mmol/L) (70 milligram per deciliter \[mg/dL\]).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With At Least One Severe and/or Confirmed Nocturnal Hypoglycemia From Start of Week 9 to Month 6 Endpoint | 36.1 | 46.0 |
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Average was assessed by the mean of at least 3 SMPG calculated over the 7 days preceding the assessment visit.
| mmol/L | HOE901-U300 | Lantus |
|---|---|---|
| Change in Average Preinjection Self-Monitored Plasma Glucose (SMPG) From Baseline to Month 6 Endpoint | -0.90 ± 0.182 | -0.84 ± 0.182 |
Pre-injection SMPG was measured within 30 minutes prior to the injection of the study drug. Variability was assessed by the mean of coefficient of variation calculated as 100 multiplied by (standard deviation/mean) over at least 3 SMPG measured during the 7 days preceding the assessment visit.
| percentage of mean | HOE901-U300 | Lantus |
|---|---|---|
| Change in Variability of Preinjection SMPG From Baseline to Month 6 Endpoint | -1.10 ± 1.222 | -1.08 ± 1.222 |
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With HbA1c <7% at Month 6 Endpoint | 39.6 | 40.9 |
| mmol/L | HOE901-U300 | Lantus |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) From Baseline to Month 6 Endpoint | -1.29 ± 0.191 | -1.38 ± 0.192 |
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Percentage of Participants With FPG <5.6 mmol/L (<100 mg/dL) at Month 6 Endpoint | 26.5 | 23.2 |
Change in each time-point of 8-point SMPG profile: 03:00 hours (clock time) at night; before and 2 hours after breakfast; before and 2 hours after lunch; before and 2 hours after dinner; and at bedtime.
| mmol/L | HOE901-U300 | Lantus |
|---|---|---|
| 03:00 at Night Plasma Glucose (n=333,323) | -0.98 ± 0.248 | -1.16 ± 0.251 |
| Pre-Breakfast Plasma Glucose (n=343,333) | -1.19 ± 0.189 | -1.49 ± 0.190 |
| 2 Hours After Breakfast Plasma Glucose (n=335,326) | -1.60 ± 0.241 | -1.90 ± 0.243 |
| Pre-Lunch Plasma Glucose (n=337,331) | -1.05 ± 0.213 | -1.23 ± 0.216 |
| 2 Hours After Lunch Plasma Glucose (n=336,325) | -0.64 ± 0.280 | -0.63 ± 0.282 |
| Pre-Dinner Plasma Glucose (n=338,333) | -0.47 ± 0.261 | -0.37 ± 0.260 |
| 2 Hours After Dinner Plasma Glucose (n=331,327) | -0.96 ± 0.298 | -1.17 ± 0.298 |
| Bedtime Plasma Glucose (n=324, 325) | -0.88 ± 0.324 | -0.91 ± 0.326 |
| U/kg | HOE901-U300 | Lantus |
|---|---|---|
| Change in Daily Basal Insulin Dose From Baseline to Month 6 Endpoint | 0.28 ± 0.017 | 0.19 ± 0.017 |
DTSQ is a validated measure to assess how satisfied participants with diabetes are with their treatment and how they perceive hyper- and hypoglycemia. It consists of 8 questions which are answered on a Likert scale from 0 to 6. DTSQ treatment satisfaction score is the sum of question 1 and 4-8 scores and ranges between 0 and 36, where higher scores indicate more treatment satisfaction.
| units on a scale | HOE901-U300 | Lantus |
|---|---|---|
| Change in Treatment Satisfaction Score Using The Diabetes Treatment Satisfaction Questionnaire (DTSQs) From Baseline to Month 6 Endpoint | 2.32 ± 0.310 | 2.24 ± 0.313 |
Hypoglycemia events were Severe hypoglycemia (an event that required assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions); Documented symptomatic hypoglycemia (typical symptoms of hypoglycemia with plasma glucose level of \<=3.9 mmol/L \[70 mg/dL\]); Asymptomatic hypoglycemia (no typical symptoms of hypoglycemia but plasma glucose level \<=3.9 mmol/L); Probable symptomatic hypoglycemia (an event during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination, but was presumably caused by a plasma glucose level \<=3.9 mmol/L, symptoms treated with oral carbohydrate without a test of plasma glucose); Relative hypoglycemia (an event during which the person with diabetes reported any of the typical symptoms of hypoglycemia, and interpreted the symptoms as indicative of hypoglycemia, but plasma glucose level \>3.9 mmol/L); Severe and/or confirmed a hypoglycemia (plasma glucose \<=3.9 mmol/L).
| percentage of participants | HOE901-U300 | Lantus |
|---|---|---|
| Any Hypoglycemia Event: All Hypoglycemia | 87.4 | 92.0 |
| Severe Hypoglycemia: All Hypoglycemia | 6.7 | 7.5 |
| Documented Symptomatic: All Hypoglycemia | 74.8 | 82.8 |
| Asymptomatic: All Hypoglycemia | 70.5 | 73.4 |
| Probable Symptomatic: All Hypoglycemia | 5.7 | 8.5 |
| Relative: All Hypoglycemia | 15.8 | 21.1 |
| Severe and/or Confirmed: All Hypoglycemia | 85.9 | 91.5 |
| Any Hypoglycemia Event: Nocturnal Hypoglycemia | 55.4 | 66.2 |
| Severe Hypoglycemia: Nocturnal | 2.5 | 3.2 |
| Documented Symptomatic: Nocturnal Hypoglycemia | 44.6 | 57.2 |
| Asymptomatic: Nocturnal Hypoglycemia | 29.2 | 31.1 |
| Probable Symptomatic: Nocturnal Hypoglycemia | 2.2 | 2.7 |
| Relative: Nocturnal Hypoglycemia | 5.0 | 10.0 |
| Severe and/or Confirmed: Nocturnal Hypoglycemia | 54.5 | 64.7 |
Substudy comparing fixed dosing regimen (every 24 hours) vs. adaptive dosing regimen (every 24 +/- 3 hours) in a subset of participants randomized to HOE901-U300 and treated for 6 months.
| percentage of hemoglobin | HOE901-U300: Adaptable Dosing Intervals | HOE901-U300: Fixed Dosing Intervals |
|---|---|---|
| Change in HbA1c From Month 6 to Month 9 | 0.21 ± 0.111 | 0.15 ± 0.120 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to 12 months regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| HOE901-U300 | — | 53/404 (13.1%) | 131/404 (32.4%) |
| Lantus | — | 62/402 (15.4%) | 132/402 (32.8%) |
| Event | HOE901-U300 | Lantus |
|---|---|---|
| Atrial fibrillationCardiac disorders | 2/404 | 3/402 |
| PneumoniaInfections and infestations | 0/404 | 3/402 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/404 | 3/402 |
| Renal failure chronicRenal and urinary disorders | 0/404 | 3/402 |
| Coronary artery diseaseCardiac disorders | 3/404 | 1/402 |
| CellulitisInfections and infestations | 3/404 | 1/402 |
| OsteomyelitisInfections and infestations | 3/404 | 2/402 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/404 | 1/402 |
| Angina pectorisCardiac disorders | 0/404 | 2/402 |
| GastroenteritisInfections and infestations | 0/404 | 2/402 |
| Event | HOE901-U300 | Lantus |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 38/404 | 34/402 |
| NasopharyngitisInfections and infestations | 34/404 | 36/402 |
| BronchitisInfections and infestations | 23/404 | 30/402 |
| DiarrhoeaGastrointestinal disorders | 22/404 | 21/402 |
| InfluenzaInfections and infestations | 22/404 | 18/402 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/404 | 21/402 |
| SinusitisInfections and infestations | 21/404 | 15/402 |
Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment group and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment group to which they were randomized.
| Age, Continuous(years) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 60.1 ± 8.5 | 59.8 ± 8.7 | 60.0 ± 8.6 |
| Sex: Female, Male(Participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Female | 187 | 193 | 380 |
| Male | 217 | 210 | 427 |
| Body Mass Index (BMI)(kilogram per square meter (kg/m^2)) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 36.6 ± 6.8 | 36.6 ± 6.1 | 36.6 ± 6.4 |
| Duration of Diabetes(years) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 15.6 ± 7.2 | 16.1 ± 7.8 | 15.8 ± 7.5 |
| Basal Insulin Daily Dose(units per kilogram (U/kg)) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 0.668 ± 0.263 | 0.667 ± 0.241 | 0.668 ± 0.252 |
| Total Insulin Daily Dose(U/kg) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Mean | 1.194 ± 0.483 | 1.200 ± 0.448 | 1.197 ± 0.466 |
| Glycated Hemoglobin A1c (HbA1c)(participants) | HOE901-U300 | Lantus | Total |
|---|---|---|---|
| Less Than (<) 8% | 144 | 144 | 288 |
| Greater Than or Equal to (>=) 8% | 260 | 259 | 519 |
Showing the first 100 of 193 sites across 13 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
The record gives a start of Dec 2011, a primary completion of Jan 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 2 years 3 months after primary completion. A results delay was requested in Feb 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine